Terms: = Pancreatic cancer AND KMT2C, ENSG00000055609, MLL3, 58508 AND Prognosis
4 results:
1. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of pancreatic cancer Patients Receiving Neoadjuvant Treatment.
Yoon KA; Woo SM; Kim YH; Kong SY; Lee MK; Han SS; Kim TH; Lee WJ; Park SJ
Gut Liver; 2019 Nov; 13(6):683-689. PubMed ID: 30970447
[TBL] [Abstract] [Full Text] [Related]
3. Reduced Expression of Histone Methyltransferases kmt2c and KMT2D Correlates with Improved Outcome in pancreatic Ductal Adenocarcinoma.
Dawkins JB; Wang J; Maniati E; Heward JA; Koniali L; Kocher HM; Martin SA; Chelala C; Balkwill FR; Fitzgibbon J; Grose RP
Cancer Res; 2016 Aug; 76(16):4861-71. PubMed ID: 27280393
[TBL] [Abstract] [Full Text] [Related]
4. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Jiao Y; Yonescu R; Offerhaus GJ; Klimstra DS; Maitra A; Eshleman JR; Herman JG; Poh W; Pelosof L; Wolfgang CL; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N; Wood LD
J Pathol; 2014 Mar; 232(4):428-35. PubMed ID: 24293293
[TBL] [Abstract] [Full Text] [Related]
